SAM
ADMA icon

Shell Asset Management’s ADMA Biologics ADMA Stock Holding History

Shell Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$112K Sell
7,620
-10,043
-57% -$172K 0.01% 615
2025
Q2 		$322K Sell
17,663
-3,144
-15% -$64.1K 0.01% 611
2025
Q1 		$413K Sell
20,807
-867
-4% -$15K 0.02% 516
2024
Q4 		$372K Sell
21,674
-36
-0.2% -$677 0.02% 586
2024
Q3 		$434K Buy
+21,710
New +$338K 0.02% 540
2024
Q1 		$247K Buy
+22,106
New +$121K 0.01% 742

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Shell Asset Management's ADMA Position: Q3 2025 in Review

Shell Asset Management reduced its ADMA Biologics (ADMA) stake by 57% in Q3 2025, selling an estimated $172K and leaving 7,620 shares worth $112K. The position accounts for 0.01% of the portfolio, ranked #615.

Shell Asset Management first reported a position in ADMA in Q1 2024 and has held it in 6 quarters since. The position peaked at $434K in Q3 2024. 365 funds tracked by Wall St. Rank hold ADMA as of Q3 2025.

  • Shell Asset Management held 7,620 shares of ADMA Biologics worth $112K as of Q3 2025.
  • Shell Asset Management sold 10,043 ADMA Biologics shares in Q3 2025, an estimated $172K.
  • ADMA Biologics made up 0.01% of Shell Asset Management's portfolio in Q3 2025, its #615 holding.
  • Shell Asset Management first reported a position in ADMA Biologics in Q1 2024 and has held it in 6 quarters since.
  • Shell Asset Management's ADMA Biologics position peaked at $434K in Q3 2024.
  • 365 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.